Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Angiopoietin TIE Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Angiopoietin TIE Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Angiopoietin -TIE Growth Factor Reception pathway regulates vascular permeability and pathological vascular remodeling during inflammation, tumorigenesis, angiogenesis, and metastasis. Forming new blood vessels (angiogenesis) is an essential step in wound and tissue healing regeneration. However, angiogenesis is also an important factor for pathogenesis in conditions such as cancer and ocular neovascular disease. Increased vascular leakage from the blood vessels occurs transiently during inflammation. The unique function of the ANG-TIE pathway in vascular stabilization also makes this pathway an attractive target in sepsis, transplantation, atherosclerosis, and the vascular complications of diabetes. The ANG–TIE pathway is required for lymphatic and blood vessel improvement amid mid-gestation, and this pathway controls vascular penetrability, aggravation, and obsessive angiogenic reactions in grown-up tissues. Increased ANG2 expression has been related to a few sorts of human cancer, counting melanoma, RCC, glioblastoma, and breast and colorectal cancer (CRC) tissues. Extensive research is being conducted globally to discover new and novel molecules to be used, like bevacizumab, that is used for the treatment of many indications like Non-small Cell Lung Cancer. The development and launch of new products will thus increase the market's revenue in the forecasted years. According to the American Cancer Society 2023 report, about 85% of all lung cancers are Non-small Cell Lung Cancer (NSCLC), with an estimated 238,340 new cases of lung cancers to be diagnosed in the USA in 2023.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 202 products in multiple stages of clinical trials – 12 in Phase 4, 40 in Phase 3, 35 in Phase 2, and 28 in Phase 1 of the clinical trials.
Key Developments Of Angiopoietin -TIE
Approved Angiopoietin -TIE Molecules
Drugs in the Pipeline of Angiopoietin -TIE
Clinical Activity and Developments of Angiopoietin -TIE
As of July 2023, various companies have approximately 202 products for 928 diseases. For these diseases, many trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Avastin (bevacizumab) |
2788 |
|
Lucentis (ranibizumab) |
664 |
|
Stivarga (regorafenib) |
289 |
|
Cabometyx (cabozantinib tablet) |
248 |
|
Caprelsa (vandetanib) |
120 |
The FDA and other regulatory bodies have approved drugs like Avastin (bevacizumab) and Lucentis (ranibizumab) for the treatment of various indications. Avastin has been approved by the FDA for multiple signs like Non-small Cell Lung Cancer, Glioblastoma, Colon Cancer, Rectal Cancer, Renal cell Cancer, Cervical Cancer, Ovarian Cancer, Fallopian tube Cancer, and others. It is also combined with Tecentriq (atezolizumab) to treat Hepatocellular Carcinoma. Lucentis is indicated for the treatment of age-related Macular degeneration and treats swelling in the retina caused by Diabetes or by a blockage in the blood vessels. It has also been approved for treating disorders like retinal diseases, Retinal Vein Occlusion, Diabetes Retinopathy, and many more.
Roche’s global net sales of Lucentis in fiscal year 2022 were $1,052.48 million, 28% lower than global net sales in fiscal year 2021, $1,407.12 million. Avantis had an overall net sale of $2,206 million in the fiscal year 2022, with a 28% decrease in the sales in 2022, from which $659.36 million sales were from the USA itself. $3,178.24 million net sales of Avantis were made in the fiscal year 2021. The decline in sales has been due to intense competition from drug majors like Bayer and Novartis. Bayer’s Stivarga made 28% higher sales in the fiscal year 2022’s first 9 months as compared to the sales in 2021. Despite competitive challenges, there is a growing global market, and players are launching new products to survive.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Avastin (bevacizumab), Lucentis (ranibizumab), Stivarga (regorafenib), Cabometyx (cabozantinib tablet) and Caprelsa (vandetanib) are some of the FDA approved TIE.
These are used for the treatment of Non-small Cell Lung Cancer, Glioblastoma, Colon Cancer, Rectal Cancer, Renal cell Cancer, Cervical Cancer, Ovarian Cancer, Fallopian tube Cancer, age-related Macular degeneration and others.
Roche, Novartis, Bayer, Takeda Pharmaceuticals and Exelixis are some of the major market players for TIE.
Rising incidence of diseases improvement in technologies, development of new treatment lines in the market and rising incidence of various types of cancers like Non-small Cell Lung Cancer, Metastatic Melanoma, Cervical Cancer, Head and Neck Squamous Cell Cancer and others are the key opportunities for TIE in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.